Digene
This article was originally published in The Gray Sheet
Executive Summary
Preliminary clinical trial results show that the firm's human papillomavirus (HPV) cervical cancer screening diagnostic detected "approximately 90% of cervical cancer precursors" compared to the approximately 67% detected by Pap smears, the company announces Jan. 15. Based on 23,000 women in seven countries, the study also found the sensitivity of the HPV screen to range from 81-97% compared to the 37-84% sensitivity range for Pap smears